Exhibit 99.2 We are a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. Our lead clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, we aim to address severe unmet medical ...

DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinicalstage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of up to $75 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All ...

Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering, and Cantor is also serving as a book-running manager for the proposed offering. About Taysha Gene Therapies time to time with the SEC. These forward-looking statements speak only as of the date hereof, and Taysha disclaims any obligation to update these statements except as may be required by law. DALLAS, June 25, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinicalstage biotechnology ...

Durable improvements across consistent clinical domains in both adult and pediatric patients, including motor skills, communication/socialization, autonomic function, seizures, and an encouraging safety profile seen across adult (up to 52 weeks) and pediatric (up to 22 weeks) patients with different genetic mutation severity Initial data from first two pediatric patients showed improvements across multiple efficacy measures and clinical domains, with early evidence of developmental gains (patient one: impro ...

Company to host webcast on Tuesday, June 18, 2024, at 8:00 AM Eastern Time Date/Time: Tuesday, June 18, 2024, at 8:00 AM Eastern Time Registration: https://lifescievents.com/event/taysha-2/ The live webcast and replay will be available through Taysha's website here. About Taysha Gene Therapies Media Contact: Carolyn Hawley Taysha-Hosted Webcast Details Oral Presentation Title: TSHA-102 gene therapy for Rett syndrome: First-cohort data from the REVEAL Adolescent/Adult and Pediatric studies Date/Time: Wednesd ...

DALLAS, June 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinicalstage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 3, 2024, the Compensation Committee of Taysha's Board of Directors granted three new employees, in the aggregate, options to purchase 360,000 shares of the Company's common stock in connection with their employment. The ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Hayleigh Collins - Director, Head of Corporate Communications and Investor Relations Sean Nolan - Chief Executive Officer and Chairman Sukumar Nagendran - President and Head of Research and Development Kamran Alam - Chief Financial Officer Conference Call Participants Kristen Kluska - Cantor Fitzgerald Salveen Richter - Goldman Sachs Whitney Ijem - Canaccord Genuity Joon Lee - Truist Secur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39536 Taysha Gene Therapies, Inc. (Exact Name of Registrant as Specified in its Charter) | Delaware | 84- ...

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2023 Earnings Conference Call March 19, 2024 4:30 PM ET Company Participants Hayleigh Collins - Director, Head of Corporate Communications and Investor Relations Sean Nolan - Chief Executive Officer Sukumar Nagendran - President and Head of Research and Development Kamran Alam - Chief Financial Officer Conference Call Participants Whitney Ijem - Canaccord Elizabeth Webster - Goldman Sachs Kristen Kluska - Cantor Fitzgerald Gil Blum - Needham & Company Mehdi Gouda ...

FORWARD LOOKING STATEMENTS This presentation is intended to be viewed by investors in the U.S. only 2 TSHA-102: Lead Clinical Program in Rett Syndrome • Clinically and commercially proven AAV9 capsid with clinical activity and tolerability across multiple CNS indications • Intrathecal delivery in an outpatient setting targets key CNS regions and minimizes viral load, potentially reducing risk of systemic inflammatory response • Self-complementary technology facilitates more rapid transgene expression Proven ...